150 related articles for article (PubMed ID: 24671324)
1. Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.
Morita T; Ugai T; Tanimoto T; Matsue K
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24671324
[TBL] [Abstract][Full Text] [Related]
2. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
[TBL] [Abstract][Full Text] [Related]
3. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Adam Z; Krejčí M; Pour L; Ševčíková E
Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
[TBL] [Abstract][Full Text] [Related]
5. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
6. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y; Sunami K; Hata H; Nagafuji K; Choi I; Higuchi M; Uozumi K; Masaki Y; Tamura K;
Int J Hematol; 2010 Oct; 92(3):503-9. PubMed ID: 20824401
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
12. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
Besada E; Vik A; Koldingsnes W; Nossent JC
Int J Hematol; 2013 Jun; 97(6):800-3. PubMed ID: 23616220
[TBL] [Abstract][Full Text] [Related]
14. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
[TBL] [Abstract][Full Text] [Related]
15. Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
Moscetti A; Saltarelli F; Bianchi MP; Monarca B; De Biase L; Porrini R; Antolino G; La Verde G
Amyloid; 2011 Jun; 18 Suppl 1():152-4. PubMed ID: 21838469
[No Abstract] [Full Text] [Related]
16. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
17. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
18. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
[TBL] [Abstract][Full Text] [Related]
19. Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Bakhous A; Zhu H; Waheed S
Br J Haematol; 2013 Nov; 163(3):293. PubMed ID: 23930696
[No Abstract] [Full Text] [Related]
20. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
